Drug Trial Radar · NCT06922591
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
183
Planned (sponsor's estimate)
Start
May 31, 2025
Primary completion
Jun 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Tango Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Revolution Medicines, Inc.
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.
Conditions
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- NSCLC
- RAS Mutation
- MTAP Deletion
- Lung Cancer
- Pancreatic Cancer Metastatic
- Thoracic Cancer
Interventions
TNG462Drug
MTA cooperative PRMT5 inhibitor
RMC-9805Drug
RAS(ON) G12D selective covalent inhibitor
RMC-6236Drug
RAS(ON) multi-selective inhibitor
mFOLFIRINOXDrug
Chemotherapy
gemcitabine/nab-paclitaxelDrug
Chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Maximum Tolerated DoseTime frame: 21 days
- Phase 1: Maximum Tolerated DoseTime frame: 28 days
- Phase 2: Combination Anti-neoplastic ActivityTime frame: 12 weeks
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Scottsdale
Scottsdale, Arizona · Recruiting
Sarah Cannon Research Institute Denver
Denver, Colorado · Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Northwestern Memorial Hospital
Chicago, Illinois · Recruiting
University of Indiana
Indianapolis, Indiana · Recruiting
University of Iowa Health Care
Iowa City, Iowa · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic Cancer Center
Rochester, Minnesota · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
NYU Langone Health
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Dallas
Irving, Texas · Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Recruiting
NEXT Oncology
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.